1
|
Cucuzza S, Brosig S, Serno T, Bechtold-Peters K, Cerar J, Kammüller M, Gallou F. Modular and tunable alternative surfactants for biopharmaceuticals provide insights into Surfactant's Structure-Function relationship. Int J Pharm 2024; 650:123692. [PMID: 38081561 DOI: 10.1016/j.ijpharm.2023.123692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2023] [Revised: 12/06/2023] [Accepted: 12/07/2023] [Indexed: 12/19/2023]
Abstract
Surface-induced aggregation of protein therapeutics is opposed by employing surfactants, which are ubiquitously used in drug product development, with polysorbates being the gold standard. Since poloxamer 188 is currently the only generally accepted polysorbate alternative, but cannot be ubiquitously applied, there is a strong need to develop surfactant alternatives for protein biologics that would complement and possibly overcome known drawbacks of existing surfactants. Yet, a severe lack of structure-function relationship knowledge complicates the development of new surfactants. Herein, we perform a systematic analysis of the structure-function relationship of three classes of novel alternative surfactants. Firstly, the mode of action is thoroughly characterized through tensiometry, calorimetry and MD simulations. Secondly, the safety profiles are evaluated through cell-based in vitro assays. Ultimately, we could conclude that the alternative surfactants investigated possess a mode of action and safety profile comparable to polysorbates. Moreover, the biophysical patterns elucidated here can be exploited to precisely tune the features of future surfactant designs.
Collapse
Affiliation(s)
- Stefano Cucuzza
- Novartis Pharma AG, TRD Biologics & CGT, GDD, 4002 Basel, Switzerland
| | - Sebastian Brosig
- Novartis Pharma AG, TRD Biologics & CGT, GDD, 4002 Basel, Switzerland
| | - Tim Serno
- Novartis Pharma AG, TRD Biologics & CGT, GDD, 4002 Basel, Switzerland
| | | | - Jure Cerar
- Novartis Pharma AG, TRD Biologics & CGT, GDD, 1234 Menges, Slovenia
| | | | | |
Collapse
|
2
|
Weber J, Buske J, Mäder K, Garidel P, Diederichs T. Oxidation of polysorbates - An underestimated degradation pathway? Int J Pharm X 2023; 6:100202. [PMID: 37680877 PMCID: PMC10480556 DOI: 10.1016/j.ijpx.2023.100202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Revised: 07/03/2023] [Accepted: 07/24/2023] [Indexed: 09/09/2023] Open
Abstract
To ensure the stability of biologicals over their entire shelf-life, non-ionic surface-active compounds (surfactants) are added to protect biologics from denaturation and particle formation. In this context, polysorbate 20 and 80 are the most used detergents. Despite their benefits of low toxicity and high biocompatibility, specific factors are influencing the intrinsic stability of polysorbates, leading to degradation, loss in efficacy, or even particle formation. Polysorbate degradation can be categorized into chemical or enzymatic hydrolysis and oxidation. Under pharmaceutical relevant conditions, hydrolysis is commonly originated from host cell proteins, whereas oxidative degradation may be caused by multiple factors such as light, presence of residual metal traces, peroxides, or temperature, which can be introduced upon manufacturing or could be already present in the raw materials. In this review, we provide an overview of the current knowledge on polysorbates with a focus on oxidative degradation. Subsequently, degradation products and key characteristics of oxidative-mediated polysorbate degradation in respect of different types and grades are summarized, followed by an extensive comparison between polysorbate 20 and 80. A better understanding of the radical-induced oxidative PS degradation pathway could support specific mitigation strategies. Finally, buffer conditions, various stressors, as well as appropriate mitigation strategies, reagents, and alternative stabilizers are discussed. Prior manufacturing, careful consideration and a meticulous risk-benefit analysis are highly recommended in terms of polysorbate qualities, buffers, storage conditions, as well as mitigation strategies.
Collapse
Affiliation(s)
- Johanna Weber
- Martin-Luther-University Halle-Wittenberg, Institute of Pharmacy, Faculty of Biosciences, Wolfgang-Langenbeck-Strasse 4, Halle (Saale) 06120, Germany
| | - Julia Buske
- Boehringer Ingelheim Pharma GmbH & Co. KG, Innovation Unit, TIP, Birkendorfer Straße 65, Biberach an der Riss 88397, Germany
| | - Karsten Mäder
- Martin-Luther-University Halle-Wittenberg, Institute of Pharmacy, Faculty of Biosciences, Wolfgang-Langenbeck-Strasse 4, Halle (Saale) 06120, Germany
| | - Patrick Garidel
- Martin-Luther-University Halle-Wittenberg, Institute of Pharmacy, Faculty of Biosciences, Wolfgang-Langenbeck-Strasse 4, Halle (Saale) 06120, Germany
- Boehringer Ingelheim Pharma GmbH & Co. KG, Innovation Unit, TIP, Birkendorfer Straße 65, Biberach an der Riss 88397, Germany
| | - Tim Diederichs
- Boehringer Ingelheim Pharma GmbH & Co. KG, Innovation Unit, TIP, Birkendorfer Straße 65, Biberach an der Riss 88397, Germany
| |
Collapse
|
3
|
Zürcher D, Caduff S, Aurand L, Capasso Palmiero U, Wuchner K, Arosio P. Comparison of the Protective Effect of Polysorbates, Poloxamer and Brij on Antibody Stability Against Different Interfaces. J Pharm Sci 2023; 112:2853-2862. [PMID: 37295604 DOI: 10.1016/j.xphs.2023.06.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Revised: 06/02/2023] [Accepted: 06/02/2023] [Indexed: 06/12/2023]
Abstract
Therapeutic proteins and antibodies are exposed to a variety of interfaces during their lifecycle, which can compromise their stability. Formulations, including surfactants, must be carefully optimized to improve interfacial stability against all types of surfaces. Here we apply a nanoparticle-based approach to evaluate the instability of four antibody drugs against different solid-liquid interfaces characterized by different degrees of hydrophobicity. We considered a model hydrophobic material as well as cycloolefin-copolymer (COC) and cellulose, which represent some of the common solid-liquid interfaces encountered during drug production, storage, and delivery. We assess the protective effect of polysorbate 20, polysorbate 80, Poloxamer 188 and Brij 35 in our assay and in a traditional agitation study. While all nonionic surfactants stabilize antibodies against the air-water interface, none of them can protect against hydrophilic charged cellulose. Polysorbates and Brij increase antibody stability in the presence of COC and the model hydrophobic interface, although to a lesser extent compared to the air-water interface, while Poloxamer 188 has a negligible stabilizing effect against these interfaces. These results highlight the challenge of fully protecting antibodies against all types of solid-liquid interfaces with traditional surfactants. In this context, our high-throughput nanoparticle-based approach can complement traditional shaking assays and assist in formulation design to ensure protein stability not only at air-water interfaces, but also at relevant solid-liquid interfaces encountered during the product lifecycle.
Collapse
Affiliation(s)
- Dominik Zürcher
- Department of Chemistry and Applied Biosciences, ETH Zürich, Zürich, Switzerland
| | - Severin Caduff
- Department of Chemistry and Applied Biosciences, ETH Zürich, Zürich, Switzerland
| | - Laetitia Aurand
- Department of Chemistry and Applied Biosciences, ETH Zürich, Zürich, Switzerland
| | | | - Klaus Wuchner
- Janssen R&D, BTDS Analytical Development, Schaffhausen, Switzerland
| | - Paolo Arosio
- Department of Chemistry and Applied Biosciences, ETH Zürich, Zürich, Switzerland.
| |
Collapse
|
4
|
Petrelli F, Giannini D, Pucci C, Del Corso I, Rocchi V, Dolcher MP, Pieve G, Pratesi F, Migliorini P, Puxeddu I. Allergy Workup in the Diagnosis of COVID-19 Vaccines-Induced Hypersensitivity Reactions and Its Impact on Vaccination. Int Arch Allergy Immunol 2022; 184:54-62. [PMID: 36265449 PMCID: PMC9747735 DOI: 10.1159/000526764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2022] [Accepted: 08/17/2022] [Indexed: 01/06/2023] Open
Abstract
INTRODUCTION Immediate and delayed hypersensitivity reactions (HSR) to COVID-19 vaccines are rare adverse events that need to be prevented, diagnosed, and managed in order to guarantee adherence to the vaccination campaign. The aims of our study were to stratify the risk of HSR to COVID-19 vaccines and propose alternative strategies to complete the vaccination. METHODS 1,640 subjects were screened for vaccinal eligibility, according to national and international recommendations. Among them, we enrolled for allergy workup 152 subjects, 43 with HSR to COVID-19 vaccines and 109 at high risk of HSR to the first dose. In vivo skin tests with drugs and/or vaccines containing PEG/polysorbates were performed in all of them, using skin prick test and, when negative, intradermal tests. In a subgroup of patients resulted negative to the in vivo skin tests, the programmed dose of COVID-19 vaccine (Pfizer/BioNTech) was administered in graded doses regimen, and detection of neutralizing anti-spike antibodies was performed in these patients after 4 weeks from the vaccination, using the SPIA method. RESULTS Skin tests for PEG/polysorbates resulted positive in only 3% (5/152) of patients, including 2 with previous HSR to COVID-19 vaccines and 3 at high risk of HSR to the first dose. Among the 147 patients with negative skin tests, 97% (143/147) were eligible for vaccination and 87% (124/143) of them received safely the programmed COVID-19 vaccine dose. Administration of graded doses of Pfizer/BioNTech vaccine were well tolerated in 17 out of 18 patients evaluated; only 1 developed an HSR during the vaccination, less severe than the previous one, and all developed neutralizing anti-spike antibodies after 4 weeks with values comparable to those subjects who received the vaccine in unfractionated dose. CONCLUSION On the whole, the usefulness of the skin tests for PEG/polysorbates seems limited in the diagnosis of HSR to COVID-19 vaccines. Graded doses regimen (Pfizer/BioNTech) is a safe and effective alternative strategy to complete the vaccinal course.
Collapse
Affiliation(s)
- Fiorella Petrelli
- Immunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy
| | - Daiana Giannini
- Immunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy
| | - Celestino Pucci
- Immunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy
| | - Isabella Del Corso
- Immunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy
| | - Valeria Rocchi
- Immunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy
| | - Maria Pia Dolcher
- Immunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy
| | - Giulio Pieve
- UO Direzione Medica di Presidio, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
| | - Federico Pratesi
- Immunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy
| | - Paola Migliorini
- Immunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy
| | - Ilaria Puxeddu
- Immunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy,*Ilaria Puxeddu,
| |
Collapse
|
5
|
Bollenbach L, Buske J, Mäder K, Garidel P. Poloxamer 188 as surfactant in biological formulations - An alternative for polysorbate 20/80? Int J Pharm 2022; 620:121706. [PMID: 35367584 DOI: 10.1016/j.ijpharm.2022.121706] [Citation(s) in RCA: 27] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Revised: 03/05/2022] [Accepted: 03/26/2022] [Indexed: 01/25/2023]
Abstract
Surfactants are used to stabilize biologics. Particularly, polysorbates (Tween® 20 and Tween® 80) dominate the group of surfactants in protein and especially antibody drug products. Since decades drug developers rely on the ethoxylated sorbitan fatty acid ester mixtures to stabilize sensitive molecules such as proteins. Reasons are (i) excellent stabilizing properties, and (ii) well recognized safety and tolerability profile of these polysorbates in humans, especially for parenteral applications. However, over the past decade concerns regarding the stability of these two polysorbates were raised. The search of alternatives with preferably less reservations concerning degradation and product quality reducing issues leads, among others, to poloxamer 188 (e.g. Kolliphor® P188), a nonionic triblock-copolymer surfactant. This review sums up our current knowledge related to the characterization and physico-chemical properties of poloxamer 188, its analytics and stability properties for biological formulations. Furthermore, the advantages and disadvantages as a suitable polysorbate-alternative for the stabilization of biologics are discussed.
Collapse
|
6
|
Zhang S, Riccardi C, Kamen D, Xiao H, Li N. Monitoring polysorbate hydrolysis in therapeutic proteins using an ultrasensitive extraction-free fatty acid quantitation method. Anal Biochem 2022; 637:114472. [PMID: 34801481 DOI: 10.1016/j.ab.2021.114472] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Revised: 11/10/2021] [Accepted: 11/11/2021] [Indexed: 01/15/2023]
Abstract
Polysorbates (PSs) are surfactants commonly added to therapeutic protein drug product formulations to protect proteins from denaturation and aggregation during storage, transportation, and delivery. However, enzymatic hydrolysis of PSs has been recognized as the primary route of PS degradation in monoclonal antibody formulations, resulting in the release of free fatty acids that drive undesired particulate formation. Here, we present a rapid lipase activity assay with optimized incubation conditions for accurate quantitation of free fatty acids without a fatty acid extraction step. This assay can detect low levels of PS degradation (0.000024% PS20 degradation) within 1 day with minimal sample preparation. The levels of released free fatty acids were found to strongly correlate with the degree of PS20 degradation. The case study described herein suggests that this approach can detect low levels of PS20 degradation caused by sub-ppm lipase levels within 1 day, compared with the duration of 14 days needed for PS degradation assays based on two-dimensional liquid chromatography-charge aerosol detection.
Collapse
Affiliation(s)
- Sisi Zhang
- Analytical Chemistry, Regeneron Pharmaceuticals, Tarrytown, NY, 10591, USA
| | - Caterina Riccardi
- Formulation Group, Regeneron Pharmaceuticals, Tarrytown, NY, 10591, USA
| | - Douglas Kamen
- Formulation Group, Regeneron Pharmaceuticals, Tarrytown, NY, 10591, USA
| | - Hui Xiao
- Analytical Chemistry, Regeneron Pharmaceuticals, Tarrytown, NY, 10591, USA.
| | - Ning Li
- Analytical Chemistry, Regeneron Pharmaceuticals, Tarrytown, NY, 10591, USA
| |
Collapse
|
7
|
Zhang S, Riccardi C, Kamen D, Reilly J, Mattila J, Bak H, Xiao H, Li N. Identification of the specific causes of polysorbate 20 degradation in monoclonal antibody formulations containing multiple lipases. Pharm Res 2022. [PMID: 34981317 DOI: 10.1007/s11095-021-03160-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Accepted: 12/21/2021] [Indexed: 01/22/2023]
Abstract
PURPOSE Polysorbates (PS) are excipients used in the biotech industry to stabilize monoclonal antibody (mAb) protein products. However, PS in drug product formulations can be degraded during storage and lead to particle formation because of the limited solubility of the free fatty acids released through the enzymatic hydrolysis of PS-a process driven by residual host cell proteins, especially lipases, that are co-purified with the drugs. When multiple lipases are present, it is very difficult to know the cause for PS degradation. In this study, we aim to determine the cause of PS degradation from two lipases, lysosomal acid lipase (LAL) and lipoprotein lipase (LPL). METHODS PS degradation pattern of the drug product was compared with those induced by recombinant lipases. Correlations between the concentration of LPL or LAL and PS20 loss were compared. Specific inhibitors, LAL inhibitor lalistat2 and LPL inhibitor GSK264220A, were used to differentiate their degradation of PS in the drug products. RESULTS The complete inhibition of PS20 degradation by lalistat2 suggested that LAL, rather than LPL, was responsible for the PS20 degradation. In addition, LAL was more strongly correlated than LPL with the percentage of PS20 degradation. No PS20 degradation was observed for several mAbs containing similar levels of LPL (0.5-1.5 ppm) in the absence of LAL, suggesting that LPL concentrations below 1.5 ppm does not degrade PS20 in drug products. CONCLUSIONS LAL was determined to be the cause of the PS20 degradation. This study provides a practical strategy to determine the root cause of PS degradation.
Collapse
|
8
|
Zhang S, Xiao H, Li N. Degradation of Polysorbate 20 by Sialate O-Acetylesterase in Monoclonal Antibody Formulations. J Pharm Sci 2021:S0022-3549(21)00470-6. [PMID: 34487744 DOI: 10.1016/j.xphs.2021.09.001] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Revised: 09/01/2021] [Accepted: 09/01/2021] [Indexed: 11/22/2022]
Abstract
Polysorbates (PS) are surfactants commonly added in biologics formulations that can protect proteins from denaturation and aggregation. However, decreases in polysorbate 20 (PS20) content have been observed in some monoclonal antibody formulations, causing the formation of visible and/or subvisible particles that ultimately compromise the quality and stability of the therapeutic protein products. It was determined that the particles are mainly composed of free fatty acid, suggesting enzymatic hydrolysis of PS is responsible for the degradation of PS. Enrichment of host cell proteins (HCPs) by immunoprecipitation followed by shotgun proteomics have been utilized to identify the HCPs that can hydrolyze PS20. One HCP, sialate O-acetylesterase (SIAE), demonstrated strong enzymatic activity for PS20 degradation even at low concentration (<5 ppm level). Incubation of recombinant SIAE with PS20 resulted in a unique degradation pattern where the hydrolysis of monoester with short fatty acid chain (C12, C14) was observed but not the monoester with long fatty acid chain (C16, C18) or higher-order esters. SIAE was detected and quantitated in several formulated mAbs, and the amount of SIAE was positively correlated to PS20 degradation in these mAbs during incubation. Additional experiments also showed that when SIAE was depleted, PS20 degradation was diminished, suggesting a causality between SIAE and PS20 degradation. The lipase activity of SIAE is specific to PS20, but not to PS 80 (PS80), which contains monoesters with long chain fatty acid (C18) and higher-order esters. The specific esterase activity of SIAE on PS20 suggests a possible solution of using PS80 over PS20 to eliminate surfactant degradation in mAb products.
Collapse
|
9
|
Brovč EV, Mravljak J, Šink R, Pajk S. Degradation of polysorbates 20 and 80 catalysed by histidine chloride buffer. Eur J Pharm Biopharm 2020; 154:236-245. [PMID: 32693155 DOI: 10.1016/j.ejpb.2020.07.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Revised: 07/01/2020] [Accepted: 07/12/2020] [Indexed: 10/23/2022]
Abstract
Polysorbates are amphiphilic, non-ionic surfactants, and they represent one of the key components of biopharmaceuticals. They serve as stabilisers, and their degradation can cause particle formation, which has been an industry-wide issue over the past decade. To determine the influence of the buffers most frequently used in biopharmaceuticals on polysorbate degradation, an accelerated stability study was carried out using placebo formulations containing 0.02% polysorbates and 20 mM buffers (pH 5.5, 6.5). These included histidine chloride, sodium citrate, sodium succinate and sodium phosphate buffers. The rate of polysorbate degradation was highest in histidine chloride buffer, and therefore we further focused on the mechanism here. The predominant degradation pathway of polysorbates in this buffer was ester hydrolysis, catalysed by the imidazole moiety of the histidine. Interestingly, the presence of therapeutic proteins in the formulations slowed histidine-catalysed degradation of polysorbates in 50% of cases, with negligible degradation seen otherwise. This emphasises the complex nature of the interactions between the components of biopharmaceutical drug products. Nonetheless, there are disadvantages of using histidine chloride buffers in biopharmaceuticals that contain polysorbates. Careful consideration should be given to selection of excipients used in parenteral formulations, whereby compatibility between buffer and surfactant is of key importance.
Collapse
Affiliation(s)
- Ema Valentina Brovč
- University of Ljubljana, Faculty of Pharmacy, The Chair of Pharmaceutical Chemistry, Aškerčeva 7, SI-1000 Ljubljana, Slovenia; Global Drug Development, Technical Research & Development, Novartis, Biologics Technical Development Mengeš, Drug Product Development Biosimilars, Lek Pharmaceuticals d.d., Kolodvorska 27, SI-1234 Mengeš, Slovenia
| | - Janez Mravljak
- University of Ljubljana, Faculty of Pharmacy, The Chair of Pharmaceutical Chemistry, Aškerčeva 7, SI-1000 Ljubljana, Slovenia
| | - Roman Šink
- Global Drug Development, Technical Research & Development, Novartis, Biologics Technical Development Mengeš, Drug Product Development Biosimilars, Lek Pharmaceuticals d.d., Kolodvorska 27, SI-1234 Mengeš, Slovenia.
| | - Stane Pajk
- University of Ljubljana, Faculty of Pharmacy, The Chair of Pharmaceutical Chemistry, Aškerčeva 7, SI-1000 Ljubljana, Slovenia.
| |
Collapse
|
10
|
Brovč EV, Mravljak J, Šink R, Pajk S. Rational design to biologics development: The polysorbates point of view. Int J Pharm 2020; 581:119285. [PMID: 32240804 DOI: 10.1016/j.ijpharm.2020.119285] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2019] [Revised: 03/26/2020] [Accepted: 03/27/2020] [Indexed: 12/29/2022]
Abstract
Formulation development is an essential part of any biopharmaceuticals development programme, and this will affect quality, safety and efficacy of the final drug product. The vast majority of biopharmaceuticals on the market are therapeutic proteins; however, these are less stable compared to conventional pharmaceuticals. To counter aggregation, denaturation and surface adsorption of proteins in solution, surfactants are added to the formulations; however, the choice of the best formulation is a challenge that is faced during formulation development. Polysorbates are the most widely used surfactants in the pharmaceutical industry and are presented in >80% of commercial monoclonal antibody formulations. In this review, we provide a general overview of polysorbates and their issues, and the characteristics that have to be taken into account during formulation development. Degradation of polysorbates, namely by hydrolysis and/or oxidation, is one of the main concerns associated with their use. Furthermore, degradation of polysorbates is determined by formulation composition, pH and storage conditions, therefore underlining the importance and complexity of protein formulation development using polysorbates. A need-based approach should be used for correct selection of excipients in protein formulations that contain polysorbates.
Collapse
Affiliation(s)
- Ema Valentina Brovč
- Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, SI-1000 Ljubljana, Slovenia; Global Drug Development Technical Research & Development, Novartis, Biologics Technical Development Mengeš, Drug Product Development, Lek Pharmaceuticals d.d., Kolodvorska 27, SI-1234 Mengeš, Slovenia
| | - Janez Mravljak
- Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, SI-1000 Ljubljana, Slovenia
| | - Roman Šink
- Global Drug Development Technical Research & Development, Novartis, Biologics Technical Development Mengeš, Drug Product Development, Lek Pharmaceuticals d.d., Kolodvorska 27, SI-1234 Mengeš, Slovenia
| | - Stane Pajk
- Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, SI-1000 Ljubljana, Slovenia.
| |
Collapse
|
11
|
Szymczyk K, Zdziennicka A, Jańczuk B. Adsorption and Aggregation Properties of Some Polysorbates at Different Temperatures. J SOLUTION CHEM 2018; 47:1824-1840. [PMID: 30524153 PMCID: PMC6244871 DOI: 10.1007/s10953-018-0823-z] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Accepted: 10/19/2018] [Indexed: 11/28/2022]
Abstract
Measurements of the surface tension of aqueous solutions of polysorbates (Tween 20, Tween 60 and Tween 80) at 293, 303 and 313 K were made. On the basis of the obtained results the Gibbs surface excess concentration of the Tweens at the water–air interface and critical micelle concentrations were determined. Knowing the Gibbs surface excess concentration and taking into account the difference between the limiting area occupied by water and Tween molecules at the water–air interface, the fraction occupied by Tween molecules was established. The limiting area occupied by the Tween molecule was calculated by applying the Joos equation. The area determined in such a way was confirmed by the calculations of cross section of Tween molecules based on the bond lengths and the angles between them as well as the average distance between the molecules, taking into account their different conformations. This area was used for calculation of the standard Gibbs energy of adsorption using the Langmuir equation. The standard Gibbs energy of Tweens adsorption at the water–air interface was also calculated from the hydrophobic part of Tween molecule–water interface tension and that of hydrophobic part. Using the determined values of standard Gibbs energy of adsorption at different temperatures, the standard enthalpy and entropy values were deduced. The standard thermodynamic functions of micellization were also determined and compared to the Gibbs energy of Tween molecules interactions through the water phase.
Collapse
Affiliation(s)
- Katarzyna Szymczyk
- Department of Interfacial Phenomena, Faculty of Chemistry, Maria Curie-Skłodowska University, Maria Curie-Skłodowska Sq. 3, 20-031 Lublin, Poland
| | - Anna Zdziennicka
- Department of Interfacial Phenomena, Faculty of Chemistry, Maria Curie-Skłodowska University, Maria Curie-Skłodowska Sq. 3, 20-031 Lublin, Poland
| | - Bronisław Jańczuk
- Department of Interfacial Phenomena, Faculty of Chemistry, Maria Curie-Skłodowska University, Maria Curie-Skłodowska Sq. 3, 20-031 Lublin, Poland
| |
Collapse
|
12
|
Kang SY, Sohn KH, Lee JO, Kim SH, Cho SH, Chang YS. Intravenous tacrolimus and cyclosporine induced anaphylaxis: what is next? Asia Pac Allergy 2015; 5:181-6. [PMID: 26240796 PMCID: PMC4521168 DOI: 10.5415/apallergy.2015.5.3.181] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2015] [Accepted: 07/14/2015] [Indexed: 01/17/2023] Open
Abstract
Tacrolimus and cyclosporine have been used in various formulations, but their hypersensitivity reactions are rare in practice. Castor oil derivatives are nonionic surfactants used in aqueous preparations of hydrophobic active pharmaceutical ingredients. Castor oil derivatives that can be used as additives to tacrolimus and cyclosporine may play a role in the development of hypersensitivity reactions, especially anaphylaxis. Various immunologic and nonimmunologic mechanisms have been implicated in hypersensitivity reactions induced by castor oil derivatives. Physicians should be aware that not only the drug itself, but also its additives or metabolites could induce hypersensitivity reactions. We report a case of anaphylaxis caused by vitamin K (phytonadine), serotonin antagonist (granisetron), intravenous tacrolimus, and cyclosporine. Interestingly, the patient tolerated oral cyclosporine, which did not contain Cremophor EL or polysorbate 80.
Collapse
Affiliation(s)
- Sung-Yoon Kang
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 463-707, Korea. ; Department of Internal Medicine, Seoul National University College of Medicine, Seoul 110-799, Korea. ; Seoul National University Medical Research Center, Seoul National University College of Medicine, Seoul 110-799, Korea
| | - Kyoung-Hee Sohn
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 463-707, Korea. ; Department of Internal Medicine, Seoul National University College of Medicine, Seoul 110-799, Korea. ; Seoul National University Medical Research Center, Seoul National University College of Medicine, Seoul 110-799, Korea
| | - Jeong-Ok Lee
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 463-707, Korea. ; Department of Internal Medicine, Seoul National University College of Medicine, Seoul 110-799, Korea
| | - Sae-Hoon Kim
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 463-707, Korea. ; Department of Internal Medicine, Seoul National University College of Medicine, Seoul 110-799, Korea. ; Seoul National University Medical Research Center, Seoul National University College of Medicine, Seoul 110-799, Korea
| | - Sang-Heon Cho
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul 110-799, Korea. ; Seoul National University Medical Research Center, Seoul National University College of Medicine, Seoul 110-799, Korea
| | - Yoon-Seok Chang
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 463-707, Korea. ; Department of Internal Medicine, Seoul National University College of Medicine, Seoul 110-799, Korea. ; Seoul National University Medical Research Center, Seoul National University College of Medicine, Seoul 110-799, Korea
| |
Collapse
|